Lea C. Cunningham, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 9N248B
- Bethesda, MD 20892
Dr. Cunningham is developing clinical protocols for the prevention and treatment of hematologic malignancies associated with deleterious germline RUNX1 variants. Dr. Cunningham is also Director of the NIH Pediatric Bone Marrow Transplantation Fellowship Program.
Areas of Expertise
1) RUNX1 deficiency 2) pediatric HSCT 3) myelodysplastic syndrome 4) myeloid malignancies
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
Dr. Cunningham's two main goals are:
- To help develop novel therapies, including a dedicated transplantation protocol for patients with germline RUNX1 mutations.
- To provide a world-class Bone Marrow Transplantation and Cellular Therapy Fellowship (BMTCT) experience in the joint NIH-Children’s National Hospital to graduates of pediatric hematology/oncology programs seeking further training and expertise in BMTCT.
Acute Kidney Injury in Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation: Incidence, Risk Factors, and Outcomes
Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared with CD3-targeted T-cell depletion
An overview of the potential strategies for NK cell-based immunotherapy for acute myeloid leukemia
Harnessing formulation and clinical pharmacology knowledge for efficient pediatric drug development: Overview and discussions from M-CERSI pediatric formulation workshop 2019
Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction
Lea C. Cunningham, M.D.
The primary aim of Dr. Cunningham’s Johns-Hopkins/NIH pediatric hematology-oncology fellowship project was to identify small molecule inhibitors of RUNX1 interactions. Dr. Cunningham went on to complete a pediatric bone marrow transplantation and cellular therapy fellowship at St Jude Children’s Research Hospital. She stayed on as a physician-scientist faculty member in the Department of Bone Marrow Transplantation and Cellular Therapy where her research focused on developing targeted therapy, improved immunomodulation and transplantation methods for patients with myeloid malignancies. Dr. Cunningham returned to NIH in 2019.